YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Wall Street] hapabapa * Wells Fargo started Design Therapeutics (DSGN [https://seekingalpha.com/symbol/DSGN]) off at overweight as it sees its Friedreich ataxia candidate, DT-216P2, as having "potentially best-in-disease functional improv…
[Abstract stock market chart with multicolored candlestick patterns and numeric overlays on a dark background. Concept for trading, investing, cryptocurrency markets and digital economy presentations.] vadishzainer/iStock via Getty Images…
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Protego Biopharma, Inc., a clinical-stage biotechnology company focused on developing small-molecule drugs that target protein misfolding diseases, today announced the appointment of Jae B. Kim, MD,…
AstraZeneca AZN announced that the FDA will extend the Prescription Drug User Fee Act (PDUFA) date for reviewing the new drug application (NDA) seeking approval of camizestrant in combination with a CDK4/6 inhibitor for the first-line trea…
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), for expanded use in breast cancer. The regulatory body has n…
On May 15, 2026, Almitas Capital disclosed a purchase of 143,527 additional shares of ASA Gold and Precious Metals Limited(NYSE:ASA), an estimated $9.69 million trade based on quarterly average pricing. What happened According to a Securit…
Key Points Almitas Capital bought 143,527 shares of ASA last quarter, with an estimated transaction value of $9.69 million based on average quarterly prices. Meanwhile, the quarter-end ASA position value increased by $9.80 million, reflect…
[Wall Street New York City] aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-up moves before the bell Monday. Stock index futures (SPX [https://seekingalpha.com/symbol/SPX]) fell Monday as traders awaited Nv…
(RTTNews) - Design Therapeutics, Inc. (DSGN), will host an investor webcast today, May 18,2026, to review data from its RESTORE-FA clinical trial evaluating DT-216P2 in patients with Friedreich's ataxia. Friedreich's ataxia (FA) is a rare…
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase…
Design Therapeutics, Inc. (NASDAQ:DSGN) was among Jim Cramer’s Mad Money stock calls as he urged investors to exercise caution when it comes to red-hot AI stocks. A caller asked for Cramer’s thoughts on the company, and here’s what he had…
(RTTNews) - Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company, reported first-quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC portfolio. Company Profile Desi…
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary l…
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution CARLSBAD, Calif., March…
(RTTNews) - Several biotech and healthcare names posted notable gains in Monday's after-hours trading session, with moves driven by earnings updates, guidance announcements, and broader investor sentiment. FibroBiologics, Inc. (FBLG) led t…
CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will part…
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Design Therapeutics (DSGN [https://seekingalpha.com/symbol/DSGN]) added ~15% on Thursday after RBC Capital Markets upgraded the stock to Outperform from Sector Perform, citing a cataly…
Chaay_Tee / iStock via Getty Images Quick Read As expected, the NVIDIA results were huge, moving the market in a big way after the close yesterday and this morning. With the NVIDIA earnings out of the way, and third quarter earnings almost…
Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) Ongoing Cash…
Design Therapeutics, Inc. CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announce…
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of indus…
CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will part…
As the U.S. stock market continues to reach new heights, with major indices like the S&P 500 and Nasdaq Composite hitting all-time highs, investors are increasingly optimistic about future growth prospects. In this context, penny stocks—th…
As the S&P 500 nears a record high and airline stocks soar following strong earnings reports, investors are keeping a close eye on global trade developments and tariff uncertainties. In this context, penny stocks—often smaller or newer com…
CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an…
SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the ap…
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, with Data on Track for the First Half of…
CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will par…
Biotech stocks are naturally an exciting area for investment. Just one therapeutic breakthrough can change the whole trajectory of the company. Millions of dollars, partnerships with big-name pharmaceuticals, or even a buyout can follow. H…
Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignme…
Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Urban Outfitters, Keysight Technologies, Design Therapeutics, and Avid Technology. InvestingPro subscribers got this news first. Never mi…
Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle Company Expects to Resume a Multiple Dose Phase 1 Clinical Study with DT-216 with an…
DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composition Design Plans to Proceed with an Imp…
CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that management will presen…
Initial Datafrom Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Expected in the Third Quarter of 2023 Progress Across GeneTAC™ Small Molecule Pipeline with IND Submissions for FECD and DM1Programs On-track for the Se…
Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2023 CARLSBAD, Calif., April 24, 2023 (G…